Novo Nordisk's 30-Billion-Dollar Research Setback Overshadows a Raised Outlook
Published on 08/06/2026 at 10:31 | Redaktion boerse-global.de
The arithmetic of investor sentiment is rarely straightforward, but Novo Nordisk's recent stretch on the Copenhagen bourse offers a stark lesson: an improved forecast means little when the research engine sputters. The Danish pharma heavyweight saw its shares climb 2.29 percent on Thursday to EUR 39.60, a modest rebound after one of its most punishing weeks in recent memory. Yet even with that recovery, the stock sits 27.82 percent below its January peak of EUR 54.86.
A Writedown That Spoke Louder Than Guidance
The turbulence began Tuesday, when management lifted its full-year 2026 outlook for adjusted sales and operating profit growth to a range of 0 to minus 6 percent at constant exchange rates, an improvement over the prior expectation of a 4 to 12 percent decline. The market's response was decidedly unenthusiastic — shares initially slid as much as 7.1 percent in Copenhagen, according to Reuters and The Business Times.
The culprit was a non-cash impairment charge of DKK 6.3 billion, with DKK 4.0 billion tied solely to the pipeline candidate Monlunabant. That balance-sheet cleansing, combined with disappointing research developments, colored the perception of an otherwise solid quarter. Stripping out the writedown, adjusted revenue for the second quarter reached DKK 78.49 billion, up 7 percent at constant exchange rates, while adjusted operating profit advanced 11 percent to DKK 33.39 billion. The reported operating figure, however, fell 16 percent once the impairment was factored in.
Jefferies, which reaffirmed its "Hold" rating with a price target of DKK 285 on Thursday, characterized the quarterly numbers as "unsettled" despite the guidance hike. Bloomberg Intelligence analyst Michael Shah similarly weighed in, noting the forecast improvement was largely anticipated — the midpoint of the new guidance implies only a modest 150-basis-point lift to consensus 2026 revenue estimates, suggesting the market had already priced in the brighter outlook.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The ZEUS Blow and Its Bill
The more consequential development came from the lab rather than the ledger. Late July brought word that the Phase 3 ZEUS trial evaluating Ziltivekimab in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammatory markers had missed its primary endpoint. The failure carried a hefty price tag: Novo Nordisk said it shed roughly USD 30 billion in market capitalization in the ensuing trading sessions.
That setback cuts to the heart of the company's longer-term ambitions beyond weight management. The GLP-1 franchise remains the engine of growth — weekly prescriptions for the Wegovy portfolio in the US reached 265,000 by mid-July, and cumulative prescriptions for the oral version have surpassed 5 million since its January US launch. The pill generated DKK 3.2 billion in second-quarter sales, meeting but not exceeding analyst expectations, and has now reached its first EU market following European Commission approval in July, with launches also underway in the United Arab Emirates and the United Kingdom.
Restructuring, Buybacks, and a Watchful Market
CEO Maziar Mike Doustdar, who took the helm relatively recently, sought to steady nerves on Wednesday, ruling out major acquisitions in favor of targeted "bolt-on" deals to rebuild the pipeline. That cautious M&A posture dovetails with a broader cost-cutting program announced in September 2025, under which the company is eliminating roughly 9,000 positions worldwide — about 11 percent of its workforce — including 5,000 in Denmark, a move framed as both cost reduction and a way to "rejuvenate" growth prospects.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The share buyback program continues apace. Since February 4, the company has repurchased more than 27 million B-shares for DKK 7.53 billion under a 12-month program sized at DKK 15 billion. Two board members, Désirée Jantzen Asgreen and Elisabeth Dahl Christensen, also received 74 B-shares each on August 5 at DKK 294.30 per share under the company's centenary anniversary program.
Investors now have a clear date on the calendar: September 21, when Novo Nordisk hosts its Capital Markets Day to review strategy, operational direction, and financial targets. The technical picture remains cautious — the relative strength index sits at 40, and the stock trades 3.34 percent below its 50-day moving average. After closing last week at EUR 38.72, down 13.37 percent over seven days and nearly 30 percent off its 52-week high, the shares are caught between operational resilience and pipeline uncertainty. Jefferies' observation about "many open questions for 2027" regarding long-term competitiveness in the obesity market captures the prevailing mood: better numbers, but a narrative that has yet to convince.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
